Trial | NCT01229566  Report issue

Title

Efficacy Study to Treat Subjects With Severe Hypertriglyceridemia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase III Study to Assess Efficacy and Safety of AKR-963 Therapy in Subjects With Severe Hypertriglyceridemia

  • Phase

    Phase 3

  • Study Type

    Interventional

  • Status

    Unknown status

  • Study Participants

    240
The primary objective is to determine the efficacy of AKR963 compared to placebo and active comparator in lowering fasting triglyceride levels in patients with very high fasting triglyceride levels ≥ 500 and ≤ 1500 mg/dL.
Increases in triglyceride concentrations have been correlated with increased risk for pancreatitis as well as for coronary heart disease (Ginsberg 2001, 2002). The incidence rates for major coronary events in the Munster Heart Study increased from 4.4% among Subjects with baseline TG concentrations under 200 mg/dL to 9.3% among Subjects with TG concentrations in the 200-399 mg/dL range, and up to 13.2% in Subjects with TG levels ranging from 400-799 mg/dL (Assmann 1996).
Study Started
Oct 31
2010
Primary Completion
Jul 31
2012
Anticipated
Study Completion
Jul 31
2012
Anticipated
Last Update
Nov 24
2011
Estimate

Drug AKR-963

3600mg/day in capsules of AKR-963, Placebo, or Active Comparator

Active Comparator Active Comparator

Active comparator

Placebo Placebo Comparator

Placebo control

AKR-963 Experimental

Investigational drug

Criteria 

Inclusion Criteria:

Men and women, ages 18-79
Fasting triglyceride ≥500 mg/dL and ≤1500 mg/dL
Provide written informed consent and authorization for protected health information disclosure

Exclusion Criteria:

Women who are pregnant or lactating, or planning to become pregnant
Use of non-statin lipid-altering drugs which cannot be stopped or other supplements with potential lipid-altering effects
History of pancreatitis
History of bariatric surgery or currently on weight loss drugs or in weight loss programs
Treatment with any agent that may affect lipid levels or hepatic function
Consumption of more than 3 alcoholic beverages per day
History of cancer within last 2 years
Participation in another clinical trial involving an investigational agent in the last 30 days
Other parameters will be assessed at the study center to ensure eligibility for this study
No Results Posted